← Russell 3000 cross-section

CSTL CASTLE BIOSCIENCES INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$1.0bn
Revenue TTM
$357m
Net income TTM
$-19m
Free cash flow
$-0m
Composite score
54.3
Sector rank
#1991

Valuation

P / E
EV / EBITDA
EV / sales
2.2
FCF yield
-0.05%
Earnings yield vs 10-yr
-6.58pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-5.4%
EBITDA margin
-4.6%
ROE
-4.1%
ROIC
-15.3%
Revenue growth
3.2%

Insider activity, last 90 days

Net open-market
$-6.36m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenue is primarily generated by our DecisionDx-Melanoma risk stratification test for cutaneous melanoma (“CM”) and our TissueCypher risk stratification test for BE. The increase primarily reflects continued growth in our core revenue drivers, TissueCypher and DecisionDx-Melanoma. TissueCypher test report volume increased by 63% and 61% for the three and six months ended June 30, 2026, respectively, reflecting continued commercial adoption. …CASTLE BIOSCIENCES INC, 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →